CoronaVac is being developed by Sinovac
Sinovac is one of the over 200 candidates racing to develop an effective vaccine to rid the world of the Covid-19 pandemic.
The Chinese company has previously developed inactivated virus vaccines against the flu as well as Hep A and B.
Named CoronaVac, Sinovac’s vaccine was tested among 743 healthy adults in two trials of 600 and 143. In the larger trial, the vaccine induced neutralising antibodies in over 90% of the volunteers.
There were no adverse events reported in the trials.
Weidong Yin, chief executive of Sinovac, said: “Our phase I/II study shows CoronaVac is safe and can induce immune response. Concluding our phase I/II clinical studies with these encouraging results is another significant milestone we have achieved in the fight against Covid-19.”
Yin added that the company is investing in manufacturing facilities.
“Like with our other vaccines, we are committed to developing CoronaVac for global use as part of our mission of supplying vaccines to eliminate human diseases,” he said.
Sinovac is partnering with Insituto Butantan in Brazil to conduct further trials.
In related news, racist flyers targeting Asians were distributed in apartment complexes in Newark.